The global Complement Drug Research Services market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics, it is expected to reach 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022.
Market drivers include:
- Increasing demand for healthcare
- Technological advancements
- Rising prevalence of chronic diseases
- Increased funding from private & government organizations for the development of pharmaceutical manufacturing segments
- Rise in R&D activities for drugs
Challenges faced by the industry:
- Stringent regulations
- High costs of research and development
- Patent expirations
This Insight Report provides a comprehensive analysis of the global Complement Drug Research Services landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity.
Segmentation by Type:
- Hemolytic Assays
- ELISA Assays
- Liposome Enzymatic Assay
Segmentation by Application:
- Business Research Institute
- University Laboratory
- Others
Market by Region:
- Americas
- APAC
- Europe
- Middle East & Africa
Company's Coverage:
- Profacgen
- Svar Life Science
- ALPCO
- NAMSA
- Creative Biolabs
- Merck
- Abbott
- Labcorp
- Sino Biological
- Affilogic
Key Questions Addressed in this Report:
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market